Canrenone

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

具有抗醛固酮活性的合成孕二烯化合物。

A synthetic pregnadiene compound with anti-aldosterone activity.(In Vitro):Canrenone inhibits the production of eortieosterone, 18-hydroxydesoxyeortieosterone, 18-hydroxycorticosterone and aldosterone in a dose-dependent manner. Canrenone dose-dependently reduces platelet-derived growth factor–induced cell proliferation and motility. Canrenone inhibits the activity of the Na+/H+ exchanger 1 induced by platelet-derived growth factor.(In Vivo):Canrenone is the principal active metabolite of Spironolactone in the rat only for a limited period. During chronic treatment a difference developed between the effect of Spironolactone and Canrenone on the RAAS indicating a decrease in the anti-mineralocorticoid activity of Canrenone and an increase in the efficacy of Spironolactone.

Canrenone inhibits the production of eortieosterone, 18-hydroxydesoxyeortieosterone, 18-hydroxycorticosterone and aldosterone in a dose-dependent manner. Canrenone dose-dependently reduces platelet-derived growth factor–induced cell proliferation and motility. Canrenone inhibits the activity of the Na+/H+ exchanger 1 induced by platelet-derived growth factor.

Canrenone is the principal active metabolite of Spironolactone in the rat only for a limited period. During chronic treatment a difference developed between the effect of Spironolactone and Canrenone on the RAAS indicating a decrease in the anti-mineralocorticoid activity of Canrenone and an increase in the efficacy of Spironolactone.

Aldadiene | NSC 261713 | SC-9376 | SC-14266

Endocrinology/Hormones

GR

Mineralocorticoid Receptor

Cardiovascular Disease

——

976-71-6

340.46

C22H28O3

>98% (HPLC)

DMSO: > 10 mM

O=C1CC[C@]2(CO3)C4CC[C@]5(C3=O)[C@](O)(CCC(O)=O)CC[C@@]5([H])[C@]4([H])C=CC2=C1

3-((8R,10S,13R,14S,17R)-17-hydroxy-3,18-dioxo-2,3,8,9,11,12,14,15,16,17-decahydro-1H-10,13-(methanooxymethano)cyclopenta[a]phenanthren-17-yl)propanoic acid

(-20℃)

With Ice Pack

≥ 2 years